Skip to main content
MSF.org
  • English
  • العربية
  • Español
  • Français
MSF medical guidelines
MSF medical guidelines

Main navigation

  • Home
  • Guidelines
  • Updates
  • Order
  • About
  • Favorites
  • Contact

All guidelines

Tuberculosis

Essential drugs

English العربية Spanish French

Clinical guidelines - Diagnosis and treatment manual

English العربية Spanish French

Essential obstetric and newborn care

English العربية French

Management of A CHOLERA EPIDEMIC

English French

Management of A MEASLES EPIDEMIC

English French

Tuberculosis

English French

Public health engineering

English French
  • Authors/Contributors
  • Introduction
  • Abbreviations and acronyms
  • Chapter 1: Introduction and epidemiology
  • Chapter 2: Clinical presentation
  • Chapter 3: Diagnosis and follow-up investigations
  • Chapter 4: Diagnostic algorithms for pulmonary tuberculosis (PTB) in adults and adolescents
  • Chapter 5: Diagnosis of tuberculosis in children
  • Chapter 6: Intensive case finding in HIV-infected individuals
  • Chapter 7: Case definitions for registration
  • Chapter 8: Tuberculosis drugs and treatment regimens
  • Chapter 9: Treatment of drug-susceptible tuberculosis
  • Chapter 10: Treatment of multidrug-resistant TB (MDR-TB)
  • Chapter 11: Treatment of mono- and poly-drug resistant tuberculosis (PDR-TB)
  • Chapter 12: Co-management and treatment of HIV in TB disease
  • Chapter 13: Adherence to tuberculosis treatment
  • Chapter 14: Tuberculosis infection control
  • Chapter 15: Follow-up of staff exposed to tuberculosis
  • Chapter 16: Treatment of latent tuberculosis infection
  • Chapter 17: Monitoring and evaluation
  • Appendices
    • Appendix 1. Xpert assays
    • Appendix 2. Interpretation of Xpert assay results
    • Appendix 3. Sputum specimen: collection, storage and shipment
    • Appendix 4. Sputum smear microscopy
    • Appendix 5. Time required for diagnostic test results
    • Appendix 6. Ventilated work station (VWS) and bio-safety cabinet (BSC)
    • Appendix 7. Lymph node fine needle aspiration
    • Appendix 8. Protein estimation
    • Appendix 9. Tuberculin skin test
    • Appendix 10. Drug information sheets and patient instructions for the treatment of tuberculosis
      • Tuberculosis drug information sheets
      • Patient instructions
    • Appendix 11. Use of tuberculosis drugs in pregnant or breastfeeding women
    • Appendix 12. Dose adjustments in renal insufficiency
    • Appendix 13. Daily dose of tuberculosis drugs using fixed-dose combinations
    • Appendix 14. Monitoring of patients on drug-susceptible tuberculosis treatment
    • Appendix 15. Monitoring of patients on drug-resistant tuberculosis treatment
    • Appendix 16. Additional investigations in drug-resistant tuberculosis
    • Appendix 16. Basic TB infection control risk assessment tool
    • Appendix 17. Management of adverse effects
    • Appendix 17. Air change per hour (ACH) measurement recommendations
    • Appendix 18. Compassionate use
    • Appendix 18. Advantages and disadvantages of ventilation techniques
    • Appendix 19. Drug interactions and overlapping toxicities
    • Appendix 19. Upper room ultraviolet germicidal irradiation (UVGI) system
    • Appendix 20. Treatment supporters
    • Appendix 21. Informing the patient
    • Appendix 23. Treatment card for patients on first-line anti-TB therapy
    • Appendix 24. Tuberculosis register for patients on first-line anti-TB therapy
    • Appendix 25. Treatment card for patients on second-line anti-TB therapy
    • Appendix 26. Tuberculosis register for patients on second-line anti-TB therapy
    • Appendix 27. Respirators
    • Appendix 27. Request form for microscopy and Xpert MTB/RIF
    • Appendix 28. Surgical masks
    • Appendix 28. Request form for sputum culture, LPA and DST
    • Appendix 29. BCG vaccine
    • Appendix 29. Sputum smear microscopy register
    • Appendix 30. Xpert MTB/RIF register
    • Appendix 31. Drug-o-gram
    • Appendix 32. Quaterly report
    • Appendix 33. Report on detection and enrolment of TB cases with rifampicin and multidrug-resistance
    • Appendix 34. Report of final outcomes of drug-resistant tuberculosis
    • Appendix 35. Check-list for the evaluation of a TB service

Breadcrumb

  • Home
  • Tuberculosis
  • Appendices

Appendix 10. Drug information sheets and patient instructions for the treatment of tuberculosis

Select language:
Enter
Download
Comment
Return to top
On this page

     

     

    Update: November 2022

     

    • Tuberculosis drug information sheets
      • Amikacin (Am)
      • Amoxicillin/clavulanic acid ratio 4:1 (Amx/Clv)
      • Bedaquiline (Bdq)
      • Clofazimine (Cfz)
      • Cycloserine (Cs) or terizidone (Trd)
      • Delamanid (Dlm)
      • Ethambutol (E)
      • Ethionamide (Eto) or prothionamide (Pto)
      • Imipenem/cilastatin (Ipm/Cln)
      • Isoniazid - Standard dose (H)
      • Isoniazid - High dose (Hh)
      • Levofloxacin (Lfx)
      • Linezolid (Lzd)
      • Meropenem (Mpm)
      • Moxifloxacin (Mfx)
      • Para-aminosalicylate sodium (PAS)
      • Pretomanid (Pa)
      • Pyrazinamide (Z)
      • Rifabutin (Rfb)
      • Rifampicin (R)
      • Rifapentine (P)
      • Streptomycin (S)
    • Patient instructions
      • Patients on drug-susceptible TB treatment
      • Patients on drug-resistant TB treatment
    Path

    Book traversal links for Appendix 10. Drug information sheets and patient instructions for the treatment of tuberculosis

    • Appendix 9. Tuberculin skin test
    • Tuberculosis drug information sheets

    Send feedback about this page or ask a general question

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    MSF medical guidelines
    MSF medical guidelines
    © Médecins Sans Frontières 2023

    Footer

    • Mentions légales
    • Politique de cookies
    • Declaration de confidentialite